Hyperlipoproteinemia Type II
"Hyperlipoproteinemia Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Descriptor ID |
D006938
|
| MeSH Number(s) |
C16.320.565.398.481 C18.452.584.500.500.644.475 C18.452.648.398.481
|
| Concept/Terms |
Hyperlipoproteinemia Type II- Hyperlipoproteinemia Type II
- Hyperlipoproteinemia Type IIs
- Hyper-Low Density Lipoproteinemia
- Density Lipoproteinemia, Hyper-Low
- Density Lipoproteinemias, Hyper-Low
- Hyper Low Density Lipoproteinemia
- Hyper-Low Density Lipoproteinemias
- Lipoproteinemia, Hyper-Low Density
- Lipoproteinemias, Hyper-Low Density
- Hyper-Low-Density-Lipoproteinemia
- Hyper-Low-Density-Lipoproteinemias
- Hyperlipoproteinemia, Type II
- Hyperlipoproteinemias, Type II
- Type II Hyperlipoproteinemia
- Type II Hyperlipoproteinemias
- Hypercholesterolemia, Essential
- Essential Hypercholesterolemia
- Essential Hypercholesterolemias
- Hypercholesterolemias, Essential
- Hypercholesterolemia, Familial
- Familial Hypercholesterolemia
- Familial Hypercholesterolemias
- Hypercholesterolemias, Familial
- Hypercholesterolemic Xanthomatosis, Familial
- Familial Hypercholesterolemic Xanthomatoses
- Familial Hypercholesterolemic Xanthomatosis
- Hypercholesterolemic Xanthomatoses, Familial
- Xanthomatoses, Familial Hypercholesterolemic
- Xanthomatosis, Familial Hypercholesterolemic
- Hyperlipoproteinemia Type 2
- Hyperlipoproteinemia Type 2s
- Type 2, Hyperlipoproteinemia
- Hyper-beta-Lipoproteinemia
- Hyper beta Lipoproteinemia
- Hyper-beta-Lipoproteinemias
- Hyperbetalipoproteinemia
- Hyperbetalipoproteinemias
Hyperlipoproteinemia Type IIb- Hyperlipoproteinemia Type IIb
- Hyperlipoproteinemia Type IIbs
- Hypercholesterolemia, Autosomal Dominant, Type B
- Familial Combined Hyperlipoproteinemia
- Combined Hyperlipoproteinemia, Familial
- Combined Hyperlipoproteinemias, Familial
- Familial Combined Hyperlipoproteinemias
- Hyperlipoproteinemia, Familial Combined
- Hyperlipoproteinemias, Familial Combined
- Apolipoprotein B-100, Familial Defective
- Apolipoprotein B 100, Familial Defective
- Apolipoprotein B-100, Familial Ligand-Defective
- Apolipoprotein B 100, Familial Ligand Defective
Hyperlipoproteinemia Type IIa- Hyperlipoproteinemia Type IIa
- Hyperlipoproteinemia Type IIas
- Hyperlipoproteinemia, Type IIa
- Hyperlipoproteinemias, Type IIa
- Type IIa Hyperlipoproteinemia
- Type IIa Hyperlipoproteinemias
- Hypercholesterolemia, Autosomal Dominant
- Autosomal Dominant Hypercholesterolemia
- Autosomal Dominant Hypercholesterolemias
- Dominant Hypercholesterolemia, Autosomal
- Dominant Hypercholesterolemias, Autosomal
- Hypercholesterolemias, Autosomal Dominant
- LDL Receptor Disorder
- Disorder, LDL Receptor
- Disorders, LDL Receptor
- LDL Receptor Disorders
- Receptor Disorder, LDL
- Receptor Disorders, LDL
|
Below are MeSH descriptors whose meaning is more general than "Hyperlipoproteinemia Type II".
Below are MeSH descriptors whose meaning is more specific than "Hyperlipoproteinemia Type II".
This graph shows the total number of publications written about "Hyperlipoproteinemia Type II" by people in this website by year, and whether "Hyperlipoproteinemia Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperlipoproteinemia Type II" by people in Profiles.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
Type 2 diabetes mellitus in heterozygous familial hypercholesterolaemia: the hazardous intersection of cardiometabolic and genetic risk. Eur J Prev Cardiol. 2022 01 11; 28(16):1817-1818.
-
Limited-Variant Screening vs Comprehensive Genetic Testing for Familial Hypercholesterolemia Diagnosis. JAMA Cardiol. 2021 08 01; 6(8):902-909.
-
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis. 2021 03; 320:1-9.
-
Lifelong Reduction in LDL (Low-Density Lipoprotein) Cholesterol due to a Gain-of-Function Mutation in LDLR. Circ Genom Precis Med. 2021 02; 14(1):e003029.
-
Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
-
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020 02 18; 75(6):565-574.
-
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). Am J Cardiol. 2019 12 15; 124(12):1876-1880.
-
MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia? Clin Rev Allergy Immunol. 2018 Apr; 54(2):224-233.
-
Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)". Circulation. 2018 02 06; 137(6):641-642.